Valuation: Protagonist Therapeutics, Inc.

Market Cap 7.86B 6.9B 6.36B 5.94B 11.15B 741B 11.35B 76.28B 29.55B 365B 29.5B 28.85B 1,270B P/E 2026 *
31.3x
P/E 2027 * -102x
Enterprise Value 7.28B 6.4B 5.89B 5.51B 10.33B 687B 10.52B 70.71B 27.39B 339B 27.34B 26.75B 1,177B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 45.6x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -
1 day+1.55%
1 week+10.35%
Current month+25.09%
1 month+24.56%
3 months+19.39%
6 months+40.28%
Current year+42.59%
1 week 113.24
Extreme 113.24
126.25
1 month 92.75
Extreme 92.75
126.25
Current year 77
Extreme 77
126.25
1 year 49.38
Extreme 49.38
126.25
3 years 13.72
Extreme 13.72
126.25
5 years 6.91
Extreme 6.91
126.25
10 years 4.47
Extreme 4.47
126.25
Manager TitleAgeSince
Chief Executive Officer 69 2008-11-30
Director of Finance/CFO 52 2022-04-17
Chief Tech/Sci/R&D Officer - 2026-03-31
Director TitleAgeSince
Director/Board Member 69 2008-11-30
Chairman 71 2014-03-18
Director/Board Member 69 2016-06-30
Date Insider Type Main position Quantity % Market Cap.
06-09Fiscal year

Director

27,000 0.0420%
05-28Fiscal year

Director

27,000 0.0420%
05-11Fiscal year

Chief Executive Officer

225,000 0.3526%
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%+10.35%+128.77%+333.18% 7.86B
+1.67%+9.28%-5.05%+2.95% 45.45B
+4.82%+7.98%+358.21%+607.68% 36.09B
+1.22%+3.42%+4.60%+55.14% 30.81B
+0.83%+11.76%+18.14%-12.31% 30.98B
+0.23%-0.86%+12.75%+21.10% 24.62B
+9.43%+11.45% - - 14.78B
+3.56%+15.52%+70.86%+136.16% 14.65B
+1.88%+8.59%+13.76%+21.62% 13.3B
+2.23%+5.32%+95.15%+99.64% 12.65B
Average +2.76%+6.55%+77.46%+140.57% 23.12B
Weighted average by Cap. +2.56%+6.53%+79.26%+138.93%

Financials

2026 *2027 *
Net sales 509M 447M 412M 385M 723M 48.05B 736M 4.94B 1.92B 23.69B 1.91B 1.87B 82.31B 160M 140M 129M 121M 227M 15.08B 231M 1.55B 601M 7.43B 600M 587M 25.83B
Net income 258M 227M 209M 195M 366M 24.36B 373M 2.51B 971M 12.01B 969M 948M 41.73B -87.49M -76.85M -70.81M -66.2M -124M -8.26B -126M -850M -329M -4.07B -329M -321M -14.14B
Net Debt -574M -504M -464M -434M -815M -54.16B -829M -5.57B -2.16B -26.7B -2.16B -2.11B -92.77B -565M -496M -457M -427M -801M -53.29B -816M -5.48B -2.12B -26.27B -2.12B -2.07B -91.29B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
131
Date Price Change Volume
26-06-25 US$124.37 +1.82% 316,699
26-06-24 US$122.15 +2.68% 1,132,431
26-06-23 US$118.96 +3.42% 700,455
26-06-22 US$115.03 +1.92% 1,193,688
26-06-18 US$112.86 +1.27% 1,533,672
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
122.15USD
Average target price
118.69USD
Spread / Average Target
-2.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock